1,520 Shares in Stryker Co. (NYSE:SYK) Purchased by Perbak Capital Partners LLP

Perbak Capital Partners LLP acquired a new stake in Stryker Co. (NYSE:SYK - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 1,520 shares of the medical technology company's stock, valued at approximately $547,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Chicago Capital LLC raised its position in shares of Stryker by 3.1% in the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock valued at $70,228,000 after buying an additional 5,841 shares in the last quarter. Zhang Financial LLC grew its stake in shares of Stryker by 55.0% during the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock worth $41,366,000 after buying an additional 40,784 shares during the last quarter. Appleton Partners Inc. MA grew its stake in shares of Stryker by 5.0% during the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock worth $10,521,000 after buying an additional 1,400 shares during the last quarter. Metis Global Partners LLC grew its stake in shares of Stryker by 10.2% during the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock worth $6,064,000 after buying an additional 1,561 shares during the last quarter. Finally, US Bancorp DE grew its stake in shares of Stryker by 0.5% in the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company's stock worth $65,829,000 after purchasing an additional 976 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Stryker Trading Up 0.2 %

NYSE:SYK traded up $0.65 during mid-day trading on Thursday, hitting $374.57. 1,634,307 shares of the stock traded hands, compared to its average volume of 1,349,381. The stock has a market capitalization of $142.97 billion, a price-to-earnings ratio of 48.27, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The firm's 50 day moving average is $366.62 and its two-hundred day moving average is $373.60. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the company posted $2.50 EPS. Stryker's revenue was up 11.9% compared to the same quarter last year. On average, equities research analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.90%. The ex-dividend date was Monday, March 31st. Stryker's dividend payout ratio is currently 43.30%.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a research report on Tuesday, March 4th. StockNews.com lowered Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Citigroup reiterated a "buy" rating and set a $450.00 price target on shares of Stryker in a report on Wednesday, February 26th. Barclays upped their price target on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Finally, Needham & Company LLC restated a "buy" rating and issued a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $423.53.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.